Cargando…

A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one

BACKGROUNDS: Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL). There is no consensus concerning the optimal method to define sarcopenia in DLBCL. METHODS: We retrospectively reviewed 193 DLBCL patients treated with rituximab plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Go, Se-Il, Park, Mi Jung, Song, Haa-Na, Kim, Hoon-Gu, Kang, Myoung Hee, Kang, Jung Hun, Kim, Hye Ree, Lee, Gyeong-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564540/
https://www.ncbi.nlm.nih.gov/pubmed/28388585
http://dx.doi.org/10.18632/oncotarget.16552
_version_ 1783258251938234368
author Go, Se-Il
Park, Mi Jung
Song, Haa-Na
Kim, Hoon-Gu
Kang, Myoung Hee
Kang, Jung Hun
Kim, Hye Ree
Lee, Gyeong-Won
author_facet Go, Se-Il
Park, Mi Jung
Song, Haa-Na
Kim, Hoon-Gu
Kang, Myoung Hee
Kang, Jung Hun
Kim, Hye Ree
Lee, Gyeong-Won
author_sort Go, Se-Il
collection PubMed
description BACKGROUNDS: Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL). There is no consensus concerning the optimal method to define sarcopenia in DLBCL. METHODS: We retrospectively reviewed 193 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Sarcopenia was classified by the region where the pretreatment skeletal muscle index (SMI) was measured. RESULTS: Both the sarcopenia-L3 and sarcopenia-pectoralis muscle (PM) groups had increased incidences of severe treatment-related toxicities and treatment discontinuation compared with the non-sarcopenia-L3 and non-sarcopenia-PM groups, respectively. The sarcopenia-L3 and non-sarcopenia-L3 groups had 5-year overall survival (OS) rates of 40.5% and 67.8% (p < 0.001), respectively. The sarcopenia-PM and non-sarcopenia-PM groups had 5-year OS rates of 35.9% and 69.0% (p < 0.001), respectively. When the sarcopenia-L3 alone and sarcopenia-PM alone groups were compared, there were no differences in baseline characteristics, treatment toxicity, or survival. In multivariate analysis, when compared with the non-sarcopenia-both group, OS was significantly worse in the sarcopenia-both group (HR, 2.480; 95% CI, 1.284 – 4.792; p = 0.007), but not in patients with either sarcopenia-L3 alone or sarcopenia-PM alone (p = 0.151). CONCLUSIONS: L3- and PM-SMIs are equally useful to define sarcopenia, which is related to intolerance to R-CHOP therapy and to worse survival in patients with DLBCL. More prognostic information can be obtained when these two SMIs are combined to define sarcopenia.
format Online
Article
Text
id pubmed-5564540
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-55645402017-08-23 A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one Go, Se-Il Park, Mi Jung Song, Haa-Na Kim, Hoon-Gu Kang, Myoung Hee Kang, Jung Hun Kim, Hye Ree Lee, Gyeong-Won Oncotarget Research Paper BACKGROUNDS: Sarcopenia is known to be associated with poor clinical outcome in patients with diffuse large B-cell lymphoma (DLBCL). There is no consensus concerning the optimal method to define sarcopenia in DLBCL. METHODS: We retrospectively reviewed 193 DLBCL patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Sarcopenia was classified by the region where the pretreatment skeletal muscle index (SMI) was measured. RESULTS: Both the sarcopenia-L3 and sarcopenia-pectoralis muscle (PM) groups had increased incidences of severe treatment-related toxicities and treatment discontinuation compared with the non-sarcopenia-L3 and non-sarcopenia-PM groups, respectively. The sarcopenia-L3 and non-sarcopenia-L3 groups had 5-year overall survival (OS) rates of 40.5% and 67.8% (p < 0.001), respectively. The sarcopenia-PM and non-sarcopenia-PM groups had 5-year OS rates of 35.9% and 69.0% (p < 0.001), respectively. When the sarcopenia-L3 alone and sarcopenia-PM alone groups were compared, there were no differences in baseline characteristics, treatment toxicity, or survival. In multivariate analysis, when compared with the non-sarcopenia-both group, OS was significantly worse in the sarcopenia-both group (HR, 2.480; 95% CI, 1.284 – 4.792; p = 0.007), but not in patients with either sarcopenia-L3 alone or sarcopenia-PM alone (p = 0.151). CONCLUSIONS: L3- and PM-SMIs are equally useful to define sarcopenia, which is related to intolerance to R-CHOP therapy and to worse survival in patients with DLBCL. More prognostic information can be obtained when these two SMIs are combined to define sarcopenia. Impact Journals LLC 2017-03-24 /pmc/articles/PMC5564540/ /pubmed/28388585 http://dx.doi.org/10.18632/oncotarget.16552 Text en Copyright: © 2017 Go et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Go, Se-Il
Park, Mi Jung
Song, Haa-Na
Kim, Hoon-Gu
Kang, Myoung Hee
Kang, Jung Hun
Kim, Hye Ree
Lee, Gyeong-Won
A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one
title A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one
title_full A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one
title_fullStr A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one
title_full_unstemmed A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one
title_short A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one
title_sort comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large b-cell lymphoma - two are better than one
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564540/
https://www.ncbi.nlm.nih.gov/pubmed/28388585
http://dx.doi.org/10.18632/oncotarget.16552
work_keys_str_mv AT goseil acomparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT parkmijung acomparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT songhaana acomparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT kimhoongu acomparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT kangmyounghee acomparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT kangjunghun acomparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT kimhyeree acomparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT leegyeongwon acomparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT goseil comparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT parkmijung comparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT songhaana comparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT kimhoongu comparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT kangmyounghee comparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT kangjunghun comparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT kimhyeree comparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone
AT leegyeongwon comparisonofpectoralisversuslumbarskeletalmuscleindicesfordefiningsarcopeniaindiffuselargebcelllymphomatwoarebetterthanone